Robert Petit
CIK 1576077 · See Remarks · last filed 2026-10-30
Robert Petit is a corporate insider who has filed 64 SEC Form 4 insider transactions across 4 companies since 2013. The most recent filing, for OSTX, was dated Oct 30, 2026. Across all open-market trades the lifetime net is −$208.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $164.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ADXS.W price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
305 COLLEGE ROAD EAST
PRINCETON, NJ 08540
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OSTX | See Remarks | 200,000 | $0.82 | $164.1K | $0 | 3 | 2026-10-30 |
| Ayala Pharmaceuticals, Inc. (ADXS) Delisted | Chief Scientific Officer | 193 | $0.60 | $116 | -$7.1K | 2 | 2018-11-07 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Chief Scientific Officer | 243,660 | — | — | -$99.6K | 25 | 2018-08-01 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Scientific Officer | 123,378 | — | — | -$102.0K | 34 | 2016-10-04 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-30 | OSTX | Grant (A) | — | $0 | EDGAR |
| 2026-02-13 | OSTX | Grant (A) | — | $0 | EDGAR |
| 2025-12-19 | OSTX | Grant (A) | — | $0 | EDGAR |
| 2018-11-07 | Ayala Pharmaceuticals, Inc. (ADXS) Delisted | Mixed | −3,963 | -$2.3K | EDGAR |
| 2018-11-05 | Ayala Pharmaceuticals, Inc. (ADXS) Delisted | Sell (S) | −8,491 | -$4.8K | EDGAR |
| 2018-08-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +1,505 | $2.2K | EDGAR |
| 2018-07-02 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +15,516 | $26.9K | EDGAR |
| 2018-06-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +1,765 | $3.2K | EDGAR |
| 2018-05-02 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +1,374 | $2.2K | EDGAR |
| 2018-04-03 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | −1,082 | -$1.7K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).